BIOGNOSYS
15.3.2022 14:02:09 CET | Business Wire | Press release
Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.
Proteome editing with TPD is a new frontier of medicine, aimed at expanding the druggable proteome. Biognosys’ TrueSignature™ platform uniquely offers high-precision proteomic panels that provide actionable insights based on highly specific and sensitive, absolute quantification of pharmacodynamic and efficacy biomarkers. These custom panels allow Kymera to monitor and quantify protein degradation. The ease of transferability of the assays — from early discovery, across preclinical evaluation, to clinical development — enables integration into all stages of Kymera’s drug development process . The panels are developed and performed at Biognosys’ state-of-the-art facility, the largest high-end, GLP certified and GCP compliant mass spectrometry laboratory worldwide for large-scale proteomics contract research.
“Kymera’s novel approach to targeted protein degradation is a great example of the power of proteomics-enabled drug development,” said Kristina Beeler, Ph.D., Chief Business Officer of Biognosys . “We are glad to see the impact our TrueSignature platform is having, not only on the advancement of Kymera’s clinical trial programs, but also on patients’ lives.”
The current partnership between Kymera and Biognosys builds upon the longstanding scientific relationship between the two companies across early R&D, preclinical, and clinical settings across oncology and inflammation.
“Biognosys has been a valued partner as we continue to expand our clinical pipeline across a diverse set of diseases and indications,” said Nello Mainolfi, Ph.D., Co-Founder, President and CEO, Kymera Therapeutics . “The company’s high-precision custom proteomics panels enable us to monitor and quantify protein degradation across all aspects of drug development, including preclinical and clinical programs.”
About TrueSignature™
The Biognosys TrueSignature™ platform provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring.
Parallel Reaction Monitoring mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of up to 100 proteins.
TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel. The measurements are performed with unprecedented speed and throughput at Biognosys' state-of-the-art facility, the world's largest high-end GLP-certified and GCP-compliant mass spectrometry laboratory. For more information, visit truesignature.bio
About Biognosys
Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions, and making them widely available for pharmaceutical and biotechnology researchers, and proteomics experts. The company offers a versatile portfolio of proprietary proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut™. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005156/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Unveils Industry's Fastest UFS 5.0 Solution for Next-Gen On-Device AI Applications23.6.2026 09:10:00 CEST | Press release
Samsung’s UFS 5.0 solution achieves industry's highest data transfer speed of 10.8GB/s, enabling faster storage and processing in mobile memoryEnhanced power efficiency and smaller package to provide optimal mobile AI experiences Samsung Electronics Co., Ltd., the world leader in advanced memory technology today announced that, for the first time in the industry, it has developed the industry's fastest Universal Flash Storage (UFS) 5.0 solution, which will help enable seamless and highly efficient AI services on future mobile devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623632789/en/ Samsung Unveils Industry's Fastest UFS 5.0 Solution for Next-Gen On-Device AI Applications The milestone sets a new benchmark for the next-generation mobile memory market as the enhanced performance is expected to allow mobile device users with significantly reduced latency and faster response times when running large language mode
Varco Energy Selects NHOA Energy and IQA-Elecnor for 100MW Old Allen Road BESS23.6.2026 09:05:00 CEST | Press release
Varco Energy (Varco), a pioneering UK-based battery storage asset owner and operator backed by the Adaptogen Capital Battery Storage Fund, is pleased to announce it has signed supply contracts for its 100MW / 244MWh Old Allen Road Battery Energy Storage System (BESS) in West Yorkshire. Highlights: The Old Allen Road BESS adds 100MW to Varco’s portfolio of operational and in-construction projects, taking its operational BESS capacity to 350MW by the end of 2027, with a further 275MW in development. NHOA Energy, in consortium with IQA-Elecnor, will deliver the turnkey EPC project at Old Allen Road, with NHOA Energy supplying the BESS and IQA-Elecnor responsible for the associated balance of plant and interconnection works (33/275kV). GE Vernova has been contracted to provide the project 275kV High Voltage Transformer. The Old Allen Road BESS is a flagship project, designed to provide essential flexibility and grid-balancing services to the UK electricity system. Supply Contract Consortiu
Google and Energy Dome Advance Multi-Continent Energy Storage Buildout with First Bilateral Project in Ireland23.6.2026 09:00:00 CEST | Press release
The 23MW/200MWh CO2 Battery project marks the first bilateral commercial agreement between the companies, relieving grid congestion, promoting energy security and accelerating a 24/7 carbon-free energy solution in Ireland and beyond Today Energy Dome, a leading long-duration energy storage technology developer, and Google announced their first bilateral commercial contract for a 23MW / 200MWh CO2 Battery project located in County Offaly, Ireland. The project is part of a long-term partnership the companies announced last year to deploy Energy Dome’s CO2 Battery technology at scale and advance Google’s ambition to expand access to affordable, secure and 24/7 clean energy for grids globally. This announcement is on the back of a 19 MW/200 MWh project in Arizona announced this month by Energy Dome, Google, and the local utility SRP. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623501211/en/ Rendering of Energy Dome's CO2 B
UNIQA Unifies Customer Risk Intelligence Across 14 Countries with SymphonyAI Financial Crime Compliance Platform23.6.2026 07:07:00 CEST | Press release
Austria's leading insurer implements centralized, insurance-specific AI for customer due diligence across Central and Eastern Europe UNIQA Insurance Group, one of Austria's and Europe's leading insurers, has selected the financial crime compliance platform from SymphonyAI, a global leader in Vertical AI, to unify customer due diligence (CDD) across its Central and Eastern European footprint. With operations spanning 14 countries and approximately 17 million customers, UNIQA brings one of the most complex compliance environments in the region to a single, centralized intelligence layer. Building for complexity, not around it UNIQA sought a CDD capability that matched the complexity of a pan-European insurer: one that could classify customers across risk categories consistently, keep pace with a shifting regulatory landscape across Central and Eastern Europe, and scale across diverse markets without requiring country-by-country customization. UNIQA selected SymphonyAI following a competi
Lenovo Recognized in the Gartner® Supply Chain Top 25 for 202623.6.2026 06:00:00 CEST | Press release
Lenovo has once again been ranked in the Gartner® Supply Chain Top 25 for 2026, achieving its highest-ever ranking at seventh globally. The Gartner Supply Chain Top 25 is a renowned annual ranking of the world’s superior supply chains. Now in its 22nd year, the Gartner Supply Chain Top 25 identifies, celebrates and profiles excellence in supply chain management. Supply chain teams use the Gartner Supply Chain Top 25 to benchmark performance, transform operations and lead in the future.Lenovo ranked eighth in 2025, 10th in 2024, and eighth in 2023. AI Builds Greater Supply Chain Resilience Global supply chains have faced unprecedented disruption over the past 12 months, driven by tariffs, component shortages, and geopolitical tensions. Lenovo’s strength amid these challenging circumstances has been its ability to build on its AI infrastructure behind its global supply chain, improving resilience, adaptability and execution at speed and scale. Over the past year, Lenovo has evolved its S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom